<scp>Coronavirus disease 2019 (COVID‐19)</scp> risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the <scp>PETReA</scp> trial

S. Williams has received honoraria from AbbVie, AstraZeneca, Roche, Takeda and BeOne and meeting support from AbbVie, AstraZeneca, Takeda and BeOne. F. Miall, V. Warbey, M. Macheta, A. Zhelyazkova, Y. J. Lim, R. Cooper, C. Gamble and H. Short have no conflicts of interest to declare. A. Arumainathan has received meeting support from Kyowa Kirin and Takeda. T. A. Eyre has received honoraria from Roche, Gilead, Janssen, AbbVie, AstraZeneca, Incyte, BMS, Medscape, PeerView, Clinical Care Options, Limbus; payment for consulting or advisory services from Roche, Kite, Loxo Oncology, BeOne, Incyte, Autolus, Galapagos, Nurix and BMS; meeting support from Gilead and AbbVie; and research funding from Gilead and BeOne. P. McKay has received honoraria from Kite/Gilead, Incyte, Janssen, Sobi, AstraZeneca and BeOne; payment for consulting or advisory services from AbbVie, AstraZeneca, BeOne, Celgene/BMS, Epizyme/Ipsen, Kite/Gilead, Incyte, Jansse, Roche, Sobi and Takeda; and meeting support from Kite/Gilead, Janssen and Takeda. M. Young has received meeting support from AstraZeneca, Takeda and BeOne; and payment for consulting or advisory services from AstraZeneca. M. Bishton has received honoraria from Roche, Takeda, Kite/Gilead, Lilly, AbbVie, Recordati and Celltrion; payment for consulting or advisory services from Incyte, Roche, Lilly and AbbVie; and research funding from Roche and Takeda. S. Gatto has received meeting support from AbbVie. E. Heartin has received honoraria from Amgen, Takeda, Celgene, Roche and Ariad; and payment for consulting or advisory services from Pfizer, Janssen, Vifor Pharma, Gilead and AbbVie. S. Opat's institution has received research funding from AbbVie, AstraZeneca, BeOne, Gilead, Johnson and Johnson, Novartis, Pharmacyclics, Roche and Takeda. He has acted in an advisory role and received honoraria from AbbVie, AstraZeneca, BeOne, Gilead, Johnson and Johnson and Merck A. Johnston has received payment for advisory services from Gilead and Specialised Therapeutics Australia. J. Trotman has received research funding from BeOne, Cellectar and Roche. K. Linton has received educational grants from AbbVie and Genmab; payment for consultancy or advisory services from Roche, AbbVie, Genmab, Nurix Therapeutics, and BMS; and honoraria from AbbVie, BeOne and Nurix Therapeutics. A. Pettitt has received research funding from AstraZeneca, Celgene/BMS, Chugai, Gilead, GSK/Novartis and Roche. Datasets analysed during the current study are available from the corresponding author on reasonable request provided they comply with legal and regulatory requirements. Figure S1. CONSORT diagram of patients with follicular lymphoma enrolled in the PETReA trial at time of analysis. Describing induction therapy received and randomisation outcomes. Data S1. Supplementary material. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.